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Summary Cardiovascular disease is the leading cause of death in modern industrialized
countries with an aging population. This fact has fueled the need for innovative diagnostic test-
ing intended to improve coronary artery disease (CAD) patient care. Detection of myocardial
ischemia using myocardial perfusion imaging (MPI) plays an important role for CAD diagnosis and
the prediction of future risk of cardiovascular events. Positron emission tomography (PET) MPI
has high diagnostic accuracy and can estimate regional myocardial blood ﬂow (MBF) in patients
with CAD. Rubidium-82 (82Rb) is a generator-produced PET myocardial perfusion tracer and has
been widely used in North America in clinical practice. 82Rb PET has recently become available
in some cardiovascular centers in Europe and Japan. Clinical trials are expected in both regions.
82Rb PET has high diagnostic accuracy and recent data have shown its prognostic value. Thus,
82Rb PET would greatly contribute to CAD patients’ care. 82Rb PET can also be used to quantify
MBF.
This review describes the current status of 82Rb MPI from basic principles to clinical impli-
cations. This paper also highlights the recent development of MBF quantiﬁcation using 82Rb
PET.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ntroduction
oronary artery disease (CAD) continues to be a major
ause of death both in modern industrialized countries and
n developing countries. However, recent developments of
oronary risk interventions have signiﬁcantly reduced the
isk of cardiovascular events. Thus, it is desirable to develop
ccurate and widely available noninvasive diagnostic testing
o detect high-risk patients (vulnerable patients) [1].
The role of any diagnostic imaging test is to enhance
he physician’s decision-making process so as to improve
ymptoms and outcomes in patients with CAD. Tech-
iques for evaluating myocardial perfusion are important
or identifying patients with CAD and for predicting their
uture cardiovascular events. Thus, physiological informa-
ion greatly contributes to strategy management in patients
ith CAD and subjects with various coronary risk factors.
The increasing numbers of patients with CAD necessitate
he development of simple and widely available diagnostic
echniques. Positron emission tomography (PET) represents
n advanced nuclear imaging technology using molecular
robes to understand the physiological process [2]. In the
ast, clinical use of cardiac PET has been limited by the
equirement for an expensive, on-site cyclotron for radioiso-
ope production as well as expensive PET scanners. However,
he development of less expensive PET/computed tomog-
aphy (PET/CT) cameras and the increased use of PET for
ncology imaging have resulted in a wider clinical applica-
ion of cardiac PET. More than 1000 PET and PET/CT scanners
ave been installed in North America [3], and currently there
re nearly 200 PET centers in Japan. Rubidium-82 (82Rb) is
PET myocardial perfusion tracer that is produced with a
trontium-82 (82Sr)/82Rb generator and is widely used for
he diagnosis of CAD in centers without immediate access to
n on-site cyclotron [3,4]. Therefore, 82Rb perfusion studies
about 120 sites where 82Sr/82Rb generators are in use in
the USA. In Canada, The Ottawa Heart Institute manufac-
tured a 82Rb generator in 1999 and Health Canada approved
its investigational use in 2003. In response to the shortage
of Technetium-99m (99mTc) in 2009, the ARMI (Alternative
Radiopharmaceuticals for Medical Imaging) trial will support
implementation of 82Rb PET in 10 new centers across Canada
in 2010. To the best of our knowledge, the ﬁrst 82Rb human
study published outside of North America was published in
Japan by Manabe et al. [8]. Recently, some cardiovascu-
lar centers in Europe and Japan have initiated 82Rb studies
[8,9]. Thus, 82Rb could be available worldwide in the near
future.
Measurement of regional myocardial blood ﬂow (MBF)
permits the evaluation both of the physiological signif-
icance of coronary lesions and of vascular function in
subjects with coronary risk factors [2,10]. PET MBF quan-
tiﬁcation is conducted mainly using 15O-labeled water and
13N-ammonia [2,10—12]; however, 82Rb can also be used to
estimate regional MBF using appropriate mathematical mod-
els [8,13—15].
82Rb tracer characteristics
Rubidium has been studied in the context of myocardial
perfusion since the late 1950s [16]. Rubidium is rapidly
extracted from the blood and is taken up by the myocardium
in relation to myocardial perfusion, which requires energy
for myocardial uptake through Na/K-ATPase similar to
thallium-201 [17]. Most recently introduced rubidium-82
(82Rb) can generate a clear perfusion image, similar to
conventional single photon emission computed tomography
(SPECT) myocardial perfusion imaging (MPI) because 82Rb isould be applied in larger populations [5,6].
The US Food and Drug Administration (FDA) approved 82Rb
enerators for clinical use in 1989. US Medicare reimburse-
ent began in 1995 [7] and is now approximately $1500
er rest-stress study. We estimate that there are currently
a
r
t
e
wn extractable tracer. Cell membrane disruption may cause
apid washout of 82Rb from the tissue and 82Rb can iden-
ify viable myocardium [18]. In animal models, the ﬁrst-pass
xtraction fraction is 50—60% at rest and uptake decreases
ith increased ﬂow (Fig. 1) [19—21].
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myocardium as a function of MBF (right). Net extraction data o
Among PET perfusion tracers, 82Rb has the shortest phys-
ical half-life with 76 s (Table 1) [2,10]. The short physical
half-life makes 82Rb suitable for repeated and sequential
perfusion studies, which usually require 10-min intervals
(Fig. 2) [8,14]. The short half-life requires rapid image
acquisition shortly after tracer administration, which can
reduce a total study time. Because of its short half-life, 82Rb
presents limited radiation exposure for patients (5.5mSv
for 60mCi) [22]. Thus, a stress and rest 82Rb study has
11.0mSv of total body radiation exposure. By compari-
son, a 1-day 99mTc rest-stress study (10mCi + 30mCi) has
10.6—12.0mSv radiation exposure and a thallium-201 stress-
rest study (3mCi) has 18.8mSv of radiation exposure.
Average USA background radiation exposure is 3.0mSv/year
[22].
The relatively high positron energy of 82Rb of 3.15MeV is
associated with a 2.60mm RMS positron range and results in
lower spatial resolution than is seen with 13N-ammonia with
a 0.57mm RMS positron range [23].
82Rb generator and infusion system
As stated earlier, 82Rb is produced from a 82Sr/82Rb (par-
ent/daughter) generator which can be eluted every 10min
[24].
The generator encases an ion-exchange column (Fig. 3A)
of tin oxide that binds with the parent isotope, 82Sr, but
has low binding afﬁnity for 82Rb. Flushing the generator
with 0.9% NaCl solution elutes the 82Rb activity while the Sr
r
w
e
a
Table 1 Common myocardial blood ﬂow tracers.
Tracer PET/SPECT Half-life Sca
Rb-82 PET 76 s 6—1
15O-water PET 110 s 6—1
13N-ammonia PET 9.97min 2—4
99mTc sestamibi/tetrofosmin SPECT 6 h 12—
Thallium-201 SPECT 72.9 h 12—
a Radiation dose is based on the total dose of standard rest/stress pe
[22]. PET, positron emission tomography; SPECT, single photon emissionocardial blood ﬂow (MBF) (left) and the net extraction by the
based on Katoh et al. [44] and Lortie et al. [14].
emains bound to the column. Daily quality control includes
2Sr and 85Sr breakthrough measurements using a dose
alibrator and pyrogen tests of the eluate. 82Sr and 85Sr
reakthrough is based on the ratio of the eluate activity
fter sufﬁcient time for 82Rb decay and the eluate activity
mmediately after the infusion is complete. It is important
o measure 82Sr and 85Sr breakthrough because they have
iochemical afﬁnity to bone and could result in irradiation
f the radio-sensitive bone marrow. Current radioisotope
roviders guarantee the quality of the generators for
—8 weeks, at which point the available 82Rb activity is
nsufﬁcient for clinical use.
The major expense associated with 82Sr/82Rb generators
s the cost of 82Sr. However, if the generator is utilized in
high throughput clinic, this cost can be offset. Others
ave demonstrated routine use of 82Rb PET for MPI at a cost
imilar to that for 99mTc SPECT [25].
Due to the short half-life of 82Rb and the decreasing
mount of available 82Rb as the generator ages, it is nec-
ssary to use an automated infusion system to administer
he 82Rb eluted from the 85Sr/82Rb generator directory to
atients (Fig. 3B) [26]. A small and mobile infusion system
s used for eluting 82Rb as often as every 10min with low
adiation exposure to medical personnel and patients [24].
Klein et al. have developed an automatic infusion system
hich produces accurate and reproducible constant-activity
lution proﬁles of 82Rb activity, independent of parent 82Sr
ctivity in the generator (Fig. 3A and B) [26,27].
n time (min) Positron
energy
(MeV)
Radiation dosage
(mSv)a
0 3.15 16 (90mCi)
0 1.72 2.5 (60mCi)
1.19 2.4 (30mCi)
15 (dual head camera) — 12/10.6 (40mCi)
15 (dual head camera) — 25.1 (4mCi)
rfusion study and according to the data by Thompson and Cullom
computed tomography.
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omputed tomography; PET, positron emission tomography.
2Rb PET perfusion image acquisition and processing
lthough some have reported on exercise tests with 82Rb,
ecause of the short tracer half-life, stress perfusion imag-
ng is usually performed by vasodilator pharmacological
tress [3].
For accurate MBF quantiﬁcation, 82Rb should be admin-
stered in such a manner that sufﬁcient activity is present
uring the uptake phase but the camera is not saturated
uring the injection phase of the scan. This can be achieved
y customizing the injected dose to the size of the patient
nd by performing infusion over 30 s or longer, rather than
sing a fast bolus. In 2D data acquisition, approximately
0MBq/kg of 82Rb can be administered intravenously over
0—60 s followed by a serial dynamic acquisition using a PET
amera with a high-count rate and high sensitivity [3,6].
odern cameras without septa and with 3D data acquisition
re more sensitive and therefore 10MBq/kg can be used.
generator can be used as long as it passes daily quality
ssessment and has sufﬁcient activity; thus, 3D imaging can
ouble the useful life of each generator [10].
Static images acquired for 3—8min and starting 70—150 s
fter completion of tracer injection can be used for MPI
3,6]. Scanners with list mode and electrocardiogram (ECG)-
ating capabilities can use the same acquisition to generate
tatic uptake images for MPI, dynamic image sequences
or MBF quantiﬁcation, and gated images for the evalua-
ion of left ventricular (LV) function [28]. PET/CT hybrid
ystems are able to acquire CT images for attenuation cor-
ection in a fraction of the time required by PET cameras
ith transmission sources (Fig. 2) [7]. The total rest/stress
ata acquisition with a modern PET/CT can be as short as
0min (Fig. 2). Thus, it may be possible to perform 10—12
D
S
d
ie stress 82Rb PET or PET/CT myocardial perfusion imaging. CT,
est/stress studies per day with a dedicated camera and
ufﬁcient stafﬁng [28].
mage processing and common artifacts
ransaxial static images are typically reconstructed using ﬁl-
ered back projection, but iterative reconstruction methods
re becoming more common with the introduction of more
owerful computers. Iterative reconstruction algorithms can
ffer images with more favorable noise properties, better
yocardium to blood pool contrast, and higher spatial reso-
ution. Alternatively, iterative reconstruction may offer high
uality images with a lower 82Rb dose, which would further
ecrease the patient dose.
One of the advantages of PET over SPECT is that
ith proper attenuation correction, PET provides reliable
mages, particularly in large patients, patients with large
reasts, and with arms present in the ﬁeld of view (FOV).
82Rb images sometimes have excessive bowel radioactiv-
ty, which can make interpretation of the inferior region
ifﬁcult. This can often be detected with a quick recon-
truction of the rest uptake frame while the patient is still
n the bed, and can be resolved by instructing the patient to
at or drink water before repeating the image acquisition.
linical applications with relative perfusion
magingiagnosis in coronary artery disease
tandard visual perfusion imaging assessment is based on
eﬁning regional uptake relative to the maximum uptake
n the myocardium. Regions with reduced uptake (so-called
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Figure 3 (A) A cross-sectional diagram of a 82Rb generator. (B) A conceptual diagram of a 82Rb infusion system that can control
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pthe Rb activity infusion proﬁle. The generator valve is modulat
patient. The radioactivity counter is used by the control system
from the patient line at the end of the infusion.
defects) represent functionally signiﬁcant CAD (Fig. 4). This
approach is applied for PET as well as SPECT MPI.
Recently, the Canadian Cardiovascular Society and col-
leagues conducted a systematic literature review for 82Rb
and 13N-ammonia PET MPI in CAD diagnosis. The mean sensi-
tivity and speciﬁcity of PET MPI are 89% and 89% with ranges
from 83% to 100% and 73% to 100% in 14 studies including a
total of 1460 patients [4]. Among the 14 studies, 6 studies
evaluated the CAD diagnostic accuracy by 82Rb. To date, a
total of 9 studies, with a total of 1151 patients, evaluated
the diagnostic accuracy. The sensitivity and speciﬁcity are
similar to the previous systematic review with 87.7% and
88.7% [29—37] (Table 2). Three recent studies used hybrid
PET/CT scanners and showed similar sensitivity of 87.8%,
and higher speciﬁcity of 95.7% [29,30,34]. Newer imaging
crystals (e.g., LSO and BGO) can obtain higher count rates
accompanied by the new generations of electronics. This
may contribute to improved diagnostic accuracy using PET,
a
S
N
tcontrol the concentration of Rb activity administered to the
for quality assessment. The system can also ﬂush the activity
y providing more counts for better image quality. Sampson
t al. evaluated diagnostic accuracy of CAD using a PET/CT
canner. The sensitivity, speciﬁcity, and accuracy were 92%,
3%, and 87%, respectively. The diagnostic accuracy of 82Rb
ith PET/CT was also high in obese patients and women,
ho usually have poor image quality in most of the diagnos-
ic imaging [34]. 82Rb PET may play an important role for
hese challenging populations.
Three studies have compared the diagnostic accuracy for
etecting CADwith PET stress perfusion imaging and conven-
ional SPECT stress perfusion imaging in the same patient
opulation. The ﬁrst two studies, which compared 82Rb
ET with thallium-201 SPECT, included a greater number of
atients with suspected CAD and showed higher sensitivity
nd speciﬁcity of PET perfusion imaging [31,36]. Today, 99mTc
PECT MPI has largely replaced thallium-201 SPECT in many
orth American facilities because 99mTc SPECT MPI has bet-
er image quality than thallium-201 due to its higher photon
168 K. Yoshinaga et al.
Figure 4 Representative images from normal subject and 47-year-old man with coronary artery disease (CAD). (A) Normal subject:
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ahe 82Rb positron emission tomography (PET) images show norma
ood image quality without any tissue attenuation artifact. (B
LAD)#6: 82Rb PET images show reversible perfusion defect in a
nergy and more widely administered activities. Important
ata from Bateman et al. evaluated the diagnostic accuracy
f ECG-gated 82Rb PET MPI compared with ECG-gated 99mTc
estamibi SPECT in 112 studies. Using a 50% threshold of epi-
ardial coronary artery stenosis, the diagnostic accuracy was
igher in 82Rb PET than in SPECT (p = 0.002) [29]. Overall, the
ccuracy for the detection of coronary artery disease from
ooled data derived from these 3 studies with 395 patients
as greater for 82Rb PET than for SPECT with greater sensi-
ivity of 98% versus 80%, speciﬁcity of 89% versus 65%, and
iagnostic accuracy of 89% versus 77%.
PET MPI has several advantages over the conventional
PECT MPI. (a) The higher sensitivity of PET cameras means
ore photons are obtained from the myocardium, and
igher quality myocardial images are provided. (b) Accurate
orrection of photon attenuation can be performedwith PET.
his contributes to reducing attenuation artifact. (c) 82Rb
o
w
P
v
Table 2 Diagnosis of coronary artery disease using 82Rb PET and
Author Year Pt (n) Stress protocol
Estevesa [30] 2008 75 Ado
Sampson [34] 2007 64 Ado/Dipy Dob
Bateman [29] 2006 112 Dipy
Williamsa [37] 1994 287 Dipy
Marwick [33] 1992 74 Dipy
Grover-McKay [32] 1992 31 Dipy
Simonea [35] 1992 225 Dipy
Stewart [36] 1991 81 Dipy
Go [31] 1990 202 Dipy
Total +weighted mean 1151
Non-weighted mean
PET/CT: total weighted mean 251
PET: total weighted mean 900
Ado, adenosine; CAG, coronary angiography; CT, computed tomograph
tomography.
a Retrospective study.
b Other cut-offs reported.fusion at stress and rest. The attenuation correction contributes
D patient with 99% stenosis in left anterior descending artery
or, indicating myocardial ischemia in LAD territory.
as relatively high extraction fractions which may permit
etection of mild degrees of ischemia. These advantages
f 82Rb PET may be particularly important for the com-
arison of perfusion imaging with PET versus SPECT using
echnetium-99m perfusion agents that have lower extrac-
ion fraction than does thallium-201. (d) Stress perfusion
bnormalities can be identiﬁed with conventional SPECT in
he majority cases; however, the interpretation of PET per-
usion images is less equivocal, possibly due to the better
uality images [29].
It is difﬁcult to detect multivessel CAD using relative
PI. Transient ischemic dilatation (TID) is considered to be
marker of extensive myocardial ischemia in either SPECT
r PET relative perfusion imaging. TID is probably associated
ith extensive ischemia and prolonged systolic dysfunction.
atients with multivessel or left main CAD have reduced left
entricular ejection fraction (LVEF) during vasodilator stress
PET/CT.
PET camera Reference CAG Sensitivity
(%)
Speciﬁcity
(%)
PET/CT >50%b 86 100
PET/CT ≥70% 93 83
PET/CT >50%b 86 100
PET >67% 87 88
PET >50% 90 100
PET >50% 100 73
PET >67% 83 91
PET QCA> 50% 83 86
PET >50% 93 78
87.7 88.7
89.0 88.8
87.8 95.7
87.7 86.8
y; Dipy, dipyridamole; Dob, dobutamine; PET, positron emission
sion
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[28]. Thus, adding functional information during stress may
contribute to excluding severe CAD.
Prognosis in coronary artery disease
Assessment of prognosis in patients with suspected or known
CAD is important for patient management. SPECT MPI stud-
ies have shown excellent prognostic value, and patients with
normal stress perfusion imaging have a low hard cardiac
event rate (<1% year). In an early report using 82Rb, PET MPI
ﬁndings were independent predictors of cardiac death and
total cardiac events. The results of PET MPI had incremen-
tal prognostic value over clinical and angiographic ﬁndings
alone [38]. Chow et al. showed a very low hard cardiac event
rate (0.09%/year) in a group of patients with normal 82Rb PET
MPI based on clinical reports [39]. Yoshinaga et al. reported
that normal PET MPI had a low annual hard cardiac event
rate (0.4%) and patients with a PET perfusion defect had
higher hard cardiac events rates (2.3% and 7.0% for mild
and moderate to severe) with stress 82Rb perfusion studies
(Fig. 5A). Importantly, 82Rb PET also seems to provide prog-
nostic value in patients whose diagnosis remains uncertain
after SPECT MPI and in obese patients (Fig. 5B) [6]. This
study further expands the importance of PET MPI especially
in prognostic value, and PET MPI may be useful in this impor-
tant population. These 3 studies represent a relatively small
sample size for prognostic evaluation. A much anticipated
larger sample size study was conducted by Lertsburapa et
al. This study showed that integration of LV function dur-
ing pharmacological stress with MPI interpretation enhanced
risk stratiﬁcation [5]. Changes between rest LVEF and LVEF
during vasodilator stress using 82Rb gated PETwere also asso-
ciated with cardiac events [40]. Schenker et al. evaluated
the incremental value of combining coronary artery calcium
(CAC) scoring and stress/rest 82Rb PET perfusion data. A
stepwise increase occurred in the risk of cardiac events with
increasing CAC with and without ischemia on PET MPI [41].
Cardiac event risk over 2—3 years may be addressed in
the patient report based on the following risk stratiﬁcations.
ACC/AHA/ASNC guidelines recommend semi-quantitative
d
b
c
a
s
Figure 5 (A) Risk-adjusted survival, free from any (total) cardiac
survival free from any (total) cardiac events as a function of norm
tomography myocardial perfusion imaging in patients with obesity
author and the Journal of the American College of Cardiology).imaging 169
nalysis (normal perfusion = 0, mild = 1, moderate = 2,
evere = 3, and absent uptake = 4) using a 17-segment model
3,42]. Using this approach, the summed perfusion defect
core can be calculated, and this score system contributes
standardization of risk stratiﬁcation. Yoshinaga et al. also
eported that abnormal cut-off value of summed stress score
4 can be applied to 82Rb PET studies with the 17-segment
odel [6].
linical indication for relative perfusion imaging
he high diagnostic accuracy and prognostic values of
ET MPI can contribute to better management of CAD
atients. Current ACC/AHA/ASNC clinical guidelines and the
oint position statement by CCS/CAR/CANM/CNCS/CanSCMR
ddressed that patients with an intermediate likelihood of
AD, when patients have had a non-diagnostic, equivocal
PECT MPI or other noninvasive tests, have indications for
ET MPI for diagnosis and detection of ischemia as Class I
ndication (evidence level B) [4,42].
ssessment of absolute myocardial blood ﬂow
sing 82Rb PET
uantitative measurement of MBF is one of the great
dvances over PET MPI, and provides a noninvasive means
o determine the functional severity of coronary steno-
is [2,10,11]. While coronary angiography deﬁnes stenosis
everity on the basis of morphologic alterations, the
easurement of MBF or ﬂow reserve represents a more phys-
ological evaluation of myocardial cellular perfusion as the
et result of antegrade epicardial coronary ﬂow and collat-
ral circulation.
Cardiovascular risk factors associated with atheroscle-
osis may cause reduction of coronary vasomotor function
espite angiographically normal coronary arteries. PET has
een used extensively to investigate the relationship of
oronary vascular function and risk factors for coronary
rtery disease, including hypercholesterolemia, diabetes,
moking, and hypertension [2,10,11].
events, as a function of summed stress score. (B) Unadjusted
al and abnormal summed stress score on positron emission
(body mass index ≥30 kg/m2) [6]. (with the permission of the
170 K. Yoshinaga et al.
Table 3 Normal values in baseline myocardial blood ﬂow and coronary ﬂow reserve.
Stress agent Numbers
of subjects
Age
(years)
Data
analysis
MBF at rest MBF at hyperemia CFR
Lin [52] Dipy 11 44 2-comp 1.15 ± 0.46 2.50 ± 0.54 —
Wassenaar [48] Dipy 15 34± 6 Retention 0.95 ± 0.35 3.0 ± 0.70 3.2 ± 0.8
Lortie [46] Dipy 14 31± 7 2-comp 0.69 ± 0.14 2.83 ± 0.81 4.25 ± 1.37
Manabe [8] ATP 15 29± 9 2-comp 0.77 ± 0.25 3.35 ± 1.37 4.47 ± 1.47
El Fakhri [53] Dipy 22 48± 12 2-comp 1.14 ± 0.19 2.81 ± 1.02 2.51 ± 0.89
Total Weighted mean 77 37 0.95 2.91 2.98
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ATP, adenosine triphosphate; CFR, coronary ﬂow reserve; Dipy, d
model.
82Rb PET MBF quantiﬁcation has been applied on a limited
cale, even though it is possible to quantify regional MBF
s well as other PET ﬂow tracers, such as 15O-water and
3N-ammonia [2,10,13,43].
The extraction fraction of 82Rb is 70% at rest and is rel-
tively consistent at physiological MBF range (Fig. 1) [13].
owever, the extraction decreases in a nonlinear manner
t high ﬂow range. Therefore, a ﬂow-dependent extraction
orrection is required [14]. In human studies these extrac-
ion fractions are calibrated to other tracers [14,44,45] and
n practice can correct for biases in the image processing
orkﬂow.
Recent studies have focused on developing MBF mea-
urements using 82Rb. Recently we have been witnessing
uch development in this ﬁeld [7]. The steps toward
linical application of quantitative MBF include basic experi-
ents, model analysis, accuracy validation with established
easurements, and conﬁrmation of repeatability of the
easurements.
racer kinetics
bsolute measurements of physiological or biochemical
unction are obtained by tracer kinetics. A parametric
hysical model is ﬁt to the time—activity curves (TAC) of
he arterial blood input function, Ca(t), and myocardial
esponse function Cm(t). Ca(t) is usually measured using a
egion of interest (ROI) in the LV cavity, and Cm(t) is sampled
n varying regions of themyocardium. Themodel parameters
re used to estimate quantitative rate constants.
A simple net retention model can be used to calculate
bsolute MBF directly from short dynamic sequential images
15]. The net retention equals the measured radiotracer
oncentration at time t divided by the integral of the blood
nput function curve to that time or an earlier time point.
ur group initially applied a simple net retention model for
BF quantiﬁcation and then shifted to compartment models
8,46—48].
Compartment models have been developed for MBF quan-
iﬁcation. The compartments represent tissue volumes that
nclude physical factors (arterial blood and intracellular
uid) or biochemical factors (tracer compound and labeled
etabolite). A mathematical model is constructed with
arameters such as a ﬂux of radioactivity between the com-
artments [49].
82Rb studies are typically modeled with a two-
ompartment model that includes activity in the vascular
d
A
t
q
t0.94 2.90 3.61
damole; MBF, myocardial blood ﬂow; 2-comp, two-compartment
pace and within the tissue compartment [50]. Following
olus injection of the tracer, predominantly unidirectional
ransport is assumed from the vascular space into the tissue
pace. A second washout parameter may also be included in
he model and may be indicative of tissue viability [51].
alidation of myocardial blood ﬂow and assessment of
epeatability
n the canine model, regional MBF can be accurately
stimated using a two-compartment model of 82Rb [51].
autamaki et al. evaluated MBF using a simple retention
pproach, and there was good agreement with low vari-
bility between microsphere ﬂow and 82Rb PET MBF in the
hysiological MBF range <3mL/g/min [45]. Lortie et al. esti-
ated 82Rb MBF using the two-compartment model and
ompared it to 13N-ammonia PET MBF in healthy volunteers
nd CAD patients. The MBF results obtained using 82Rb were
orrelated with those obtained using 13N-ammonia (r = 0.85)
ver a wide ﬂow range [46]. Although the hyperemic MBF
ata measured by 82Rb was lower than that for MBF with
ther tracers, 82Rb MBF measurements had good correlation
ith 15O-water (r = 0.94) using an appropriate noise reduc-
ion approach [52]. These data validated the accuracy of
2Rb PET MBF. Table 3 summarizes the normal values in rest
nd hyperemic MBF in normal subjects. The average rest
BF is 0.95mL/min/g and rest MBF is similar to MBF mea-
ured by other PET ﬂow tracers [2,11]. On the other hand,
verage hyperemic MBF is 2.91mL/min/g, which is slightly
ower than that measured by other PET ﬂow tracers usually
.0—5.0mL/min/g [2,11].
As the next step for clinical application, Manabe et al.
valuated the repeatability of rest and hyperemic MBF with
2Rb using 2D acquisition and a two-compartment model.
BF measurements with 82Rb showed high reproducibility
ith the repeatability coefﬁcient 0.19mL/min/g for rest
nd 0.92mL/min/g for hyperemia [8]. Another approach of
2Rb MBF measurements using the two-compartment model
nd with factor analysis to reduce noise and spillover effects
lso showed good reproducibility [53].
ssessment of myocardial blood ﬂow in coronary artery
isease
ltered MBF and ﬂow reserve may be much more extensive
han angiographic documentation of regional CAD. 82Rb MBF
uantiﬁcation is expected to improve the detection of mul-
ivessel CAD. Parkash et al. compared quantitative MBF and
sion
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mRubidium-82 positron emission tomography myocardial perfu
traditional relative perfusion assessment in patients with
multivessel CAD. The defect sizes were signiﬁcantly larger
with the quantiﬁcation approach than with the relative per-
fusion approach [47]. Hyperemic MBF and coronary ﬂow
reserve using 82Rb were inversely correlated with epicardial
coronary artery stenosis [54]. These data agreed with pre-
vious PET studies using 15O-water and 13N-ammonia [2,11].
Accordingly, PET has been used to detect the early stages of
vascular alterations and to monitor response to therapy. Van
Tosh et al. [55] reported regions of abnormal ﬂow reserve
with PET 82Rb imaging and dipyridamole stress in the areas
of restenosis after angioplasty. Thus, PET can be used to
objectively identify patients who would beneﬁt from revas-
cularization and recovery of functional ﬂow reserve.
Quantiﬁcation of MBF with 82Rb PET is expected to
improve with newer cameras with faster count rate capabili-
ties by enabling injection of more activity without saturation
of the camera and by supporting shorter dynamic image time
frames that better measure TACs.
Coronary ﬂow reserve in relation to coronary risk factors
and evaluation of therapies
Coronary ﬂow reserve is a complex physiological parame-
ter inﬂuenced by many factors other than coronary artery
stenosis. PET perfusion studies have demonstrated reduction
of ﬂow reserve in many cardiac disorders without evidence
of coronary artery disease. As stated before, unlike other
PET ﬂow tracers, 82Rb MBF is currently being developed.
Thus, evaluations of therapeutic interventions have been
very limited.
Gould et al. evaluated increases in MBF reserve in associ-
ation with an improvement in exercise capacity and serum
lipid proﬁles [56]. This study evaluated myocardial perfu-
sion abnormality using a relative perfusion uptake approach
with either 82Rb or 13N-ammonia. Yoshinaga et al. evaluated
the effect of exercise training on regional MBF in patients
with stable CAD. The exercise training increased hyperemic
MBF in diseased segments compared to those for the seden-
tary lifestyle group (% increase in myocardial blood ﬂow:
12.5± 22.1% vs. 2.6± 16.3%, p = 0.02) (Fig. 6A and B) [57].
c
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Figure 6 (A) A patient with exercise training (top) improved hyp
there was no signiﬁcant difference between baseline and follow-
increased hyperemic myocardial blood ﬂow and hence coronary ﬂ
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hese data may indicate favorable evidence to support the
ffect of exercise training on MBF to ischemic myocardium.
ing et al. evaluated the effects of statin therapy on periph-
ral endothelial function and coronary vascular function.
imvastatin improved peripheral endothelial function but
id not improve coronary ﬂow reserve [58].
ndothelial dysfunction in patients who have coronary
isk factors
oronary endothelial dysfunction is one of the earliest
bnormalities to be seen in the development of CAD.
ndothelial dysfunction is considered to be associated with
uture cardiac events. PET MPI with cold pressor tests has
lso been applied to measure coronary endothelial function
oninvasively [2,11,12]. Preliminary data by Yoshinaga et al.
eported that normal subjects increased MBF during cold
ressor test [59]. These data need further study and further
nvestigations are currently underway.
ummary
ET MPI provides accurate evaluation of regional MBF at rest
nd during stress. The role of 82Rb PET myocardial perfusion
maging is now well established for diagnosis and risk strat-
ﬁcation of CAD. In the past, widespread clinical use has
een limited by the cost of the technology and access to
he radiotracers. However, 82Rb PET has greatly contributed
o increasing acceptance of PET for clinical practice. This
rend is expected to continue not only in North America,
ut also in Asia and Europe.
MBF quantiﬁcation using 82Rb PET has undergone exten-
ive development in recent years. Application of MBF for
he assessment of therapeutic interventions in subjects with
oronary arteriosclerosis risk is expected. 82Rb PET imaging
ay also be used for endothelial function measurements
apable of deﬁning early stage coronary arteriosclerosis.
ore studies are needed to establish this measurement.
e hope this hybrid approach will help optimize clinical
ecision-making for therapy selection and this will improve
atient outcomes.
eremic myocardial blood ﬂow in the lateral area. In contrast,
up in the control patient. (B) Exercise training signiﬁcantly
ow reserve [57] (with the permission of the author and the
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